Anal Cancer

Overview

Anal cancer is a rare but serious malignancy that develops in the anus, the short channel (approximately 3 to 4 centimeters long) at the end of the digestive tract through which stool leaves the body. The lining of the anal canal is made up of different cell types, and this variation means that more than one type of cancer can arise in this location.

The great majority of anal cancers (80 to 90 percent) are squamous cell carcinomas, originating from the flat squamous cells that line the anal canal surface. Less common types include adenocarcinoma (arising from glandular cells), basal cell carcinoma, and melanoma.

While anal cancer is relatively uncommon among all cancer types, its incidence has been rising in recent decades. This increase is closely linked to the growing prevalence of human papillomavirus (HPV) infection. High-risk HPV types (particularly HPV-16 and HPV-18) are detected in more than 80 percent of anal cancer cases.

When caught at an early stage, anal cancer has a high treatment success rate. Chemoradiotherapy (the combination of chemotherapy and radiation therapy) is now the cornerstone of anal cancer treatment and can achieve lasting cure in many patients without surgery. Early diagnosis therefore both broadens treatment options and plays a decisive role in preserving quality of life.

Symptoms

The symptoms of anal cancer are often mild in the early stages and can easily be mistaken for far more common conditions such as hemorrhoids, anal fissure, or anal infection. This overlap is one of the reasons diagnosis is sometimes delayed.

Anal cancer symptoms include the following:

• Rectal bleeding. The most frequent symptom. Bright red or dark blood may be noticed during or after bowel movements. Because the bleeding is sometimes mild and intermittent, it is often attributed to hemorrhoids. Any rectal bleeding should be evaluated by a doctor.
• Pain or pressure around the anus. A dull or throbbing ache in the anal area, which may be particularly noticeable when sitting. Pain may worsen during or after bowel movements. Some patients experience a persistent sense of fullness or pressure rather than sharp pain.
• A lump or swelling near the anus. A palpable or visible mass in or around the anal area is an important warning sign. The lump may be painful or painless and is sometimes noticed as a small protrusion or area of firmness.
• Itching and irritation. Persistent anal itching or burning (particularly when it does not respond to standard treatment) should be evaluated as a potential sign of anal cancer.
• Discharge from the anus. Bloody or mucous discharge may be present. This can sometimes be mistaken for an anal infection.
• Changes in bowel habits. Changes in stool shape (narrow or pencil-thin stools), altered bowel frequency, or a feeling of incomplete emptying may develop.
• Swollen lymph nodes in the groin. As cancer advances, it may spread to the inguinal (groin) lymph nodes, which may become palpable as painless or mildly tender masses.
• Fecal incontinence. In advanced disease, involvement of the sphincter muscles can impair the ability to control bowel movements.

A significant proportion of anal cancers produce no symptoms in the early stages, or symptoms are so mild they are dismissed. Regular examination and screening in individuals with known risk factors is therefore of considerable importance.

When to See a Doctor

While anal symptoms are most commonly caused by benign conditions, the following situations always warrant medical evaluation.

Schedule a medical evaluation if:

• You have unexplained anal bleeding, regardless of the amount
• You have persistent anal or rectal pain or discomfort lasting more than two weeks
• You have noticed a lump or swelling in or around the anal area
• You have noticed an unexplained change in your bowel habits
• You have noticed swollen lymph nodes in the groin
• You have a history of HPV infection, HIV positivity, or a previous HPV-related anal lesion and have developed a new symptom
• You have been treated for hemorrhoids but symptoms have not resolved

Neglecting anal symptoms out of embarrassment delays diagnosis and reduces the chances of successful treatment. Anal cancer caught at an early stage is highly treatable in the great majority of cases.

Causes

The exact cause of anal cancer is not fully understood, but the key factors involved in its development have been clearly identified.

• Human papillomavirus (HPV) infection. This is the most important and most common cause. High-risk HPV types (particularly HPV-16 and HPV-18) integrate into the DNA of anal canal cells, disrupting normal cell cycle regulation and driving uncontrolled cell growth. High-risk HPV is detected in more than 80 percent of anal cancer cases. HPV is transmitted through sexual contact and most often causes no symptoms.
• Anal intraepithelial neoplasia (AIN). HPV-driven precancerous cell changes in the anal canal lining. AIN can progress to invasive cancer over time, particularly when left unmonitored. High-grade AIN (AIN 2-3) requires especially careful surveillance.
• Chronic inflammation and local irritation. Longstanding anal fistula, chronic anal infection, and recurrent anal abscesses can create a chronically irritated environment that promotes malignant transformation over time.

Risk Factors

Several risk factors for anal cancer have been identified. The presence of more than one risk factor further increases overall risk.

• HPV infection. The presence of high-risk HPV types in the anal region is the most significant risk factor. Having multiple sexual partners and engaging in unprotected anal intercourse increases the risk of HPV transmission.
• HIV positivity and immunosuppression. People living with HIV (particularly those with low CD4 counts) face an anal cancer risk 30 to 40 times higher than the general population. Individuals on long-term immunosuppressive therapy following organ transplantation are also at elevated risk. When the immune system cannot suppress HPV infection, the virus remains active for longer and increases the likelihood of cellular transformation.
• History of anal intercourse. Anal intercourse increases the risk of HPV transmission and therefore also raises anal cancer risk. This applies to both men and women.
• Smoking. Tobacco use both weakens the immune system's ability to suppress HPV and directly introduces carcinogens into the body. Anal cancer risk is substantially higher in smokers than in non-smokers.
• Sex and age. Anal cancer is slightly more common in women than in men. Diagnosis most often occurs after the age of 60, though in HIV-positive individuals it can arise at considerably younger ages.
• History of cervical, vulvar, or vaginal cancer. These cancers are also largely HPV-driven. A personal history of any of them is associated with an increased risk of anal HPV infection and anal cancer.
• Long-standing anal fistula and chronic inflammation. Particularly in fistulas that have gone untreated for years, the risk of malignant transformation is increased.

Diagnosis

Anal cancer is diagnosed through a combination of physical examination, imaging, and biopsy. A definitive diagnosis must always be confirmed by tissue biopsy.

Diagnostic methods include the following:

• Physical examination and digital rectal examination. External inspection of the anal area and a finger examination of the anal canal assess for mass, firmness, and tenderness. The groin lymph nodes are also palpated. This straightforward examination is often the first step that leads toward diagnosis.
• Anoscopy and proctoscopy. Allow direct visualization of the anal canal and lower rectum. Suspicious lesions are identified and biopsied during anoscopy. High-resolution anoscopy (HRA) is considerably more sensitive than standard anoscopy for detecting HPV-related precancerous lesions (AIN) and is recommended for high-risk individuals.
• Biopsy. Essential for a definitive diagnosis. A small tissue sample taken from the suspicious area is examined in the pathology laboratory to confirm the presence of cancer, identify its type, and determine its grade. Biopsy can be performed during anoscopy or in the outpatient clinic.
• Endoanal ultrasonography. Evaluates the depth of tumor invasion into the sphincter muscles and assesses regional lymph node involvement. Provides important staging information.
• Computed tomography (CT). Chest, abdominal, and pelvic CT scans assess whether cancer has spread to distant organs such as the liver and lungs. Standard practice for staging and treatment planning.
• Magnetic resonance imaging (MRI). Provides high-resolution images of the tumor within the pelvis and its relationship to surrounding structures. Particularly superior to CT for assessing the tumor's involvement of the sphincter muscles and adjacent organs. Frequently used in treatment planning.
• PET-CT. Uses a radioactive tracer to map tumor activity and lymph node involvement throughout the body. Particularly valuable for staging and for assessing treatment response.
• HIV testing and CD4 count. Since HIV-positive individuals represent a high-risk group and HIV status can influence treatment decisions, HIV testing is recommended for all patients newly diagnosed with anal cancer.

Anal cancer is staged using the TNM classification system based on tumor size (T), lymph node involvement (N), and the presence of distant metastasis (M). Stage I is the most localized; stage IV indicates distant organ metastasis. Stage directly determines treatment choice and prognosis.

Treatment

Anal cancer treatment has undergone a fundamental transformation over the past thirty years. Where once the standard approach was extensive abdominal surgery (abdominoperineal resection) requiring a permanent colostomy, today chemoradiotherapy can achieve lasting cure in most patients without surgery. This development is considered the most important advance in anal cancer care, preserving both oncological outcomes and quality of life.

Treatment options include the following:

• Chemoradiotherapy (concurrent chemotherapy and radiation therapy). The standard and primary treatment modality. The most commonly used chemotherapy regimen combines mitomycin C and 5-fluorouracil (5-FU); some centers prefer cisplatin with 5-FU. Radiation therapy is delivered concurrently to the pelvis and inguinal lymph nodes. Treatment typically lasts 5 to 6 weeks. In the majority of stage I to III anal cancers, this approach achieves a complete response.
• Radiation therapy alone. For small, superficial early-stage tumors, radiation therapy without chemotherapy may be considered. However, because chemoradiotherapy produces significantly better oncological outcomes than radiation alone, this approach is reserved for carefully selected cases.
• Local excision. For small, superficial, well-defined early-stage tumors (particularly those in the perianal region), wide local excision may be appropriate. In selected cases without sphincter muscle invasion or lymph node involvement, excision with adequate margins can achieve cure.
• Abdominoperineal resection (APR). The salvage surgical procedure used when chemoradiotherapy fails to produce a complete response or when cancer recurs locally. The anus, rectum, and surrounding tissues are removed and a permanent colostomy (stoma on the abdominal wall) is created. Because this operation profoundly affects quality of life, it is reserved for situations where chemoradiotherapy has not achieved or sustained disease control.
• Immunotherapy. In anal cancers that recur after chemoradiotherapy or develop distant metastases, immune checkpoint inhibitors such as nivolumab and pembrolizumab have produced encouraging results. Clinical research in this area is expanding rapidly.
• Salvage chemotherapy. Systemic chemotherapy is used in patients with distant metastases or those who have not responded to standard treatment. Cisplatin and 5-FU-based regimens are commonly employed.
• Treatment in HIV-positive patients. Chemoradiotherapy is effective in HIV-positive individuals, though the risk of toxicity is higher. Maintaining active antiretroviral therapy (ART) throughout treatment supports immune function and improves treatment tolerability. HIV-positive patients are best managed by experienced multidisciplinary teams.

Complications

Complications of anal cancer and its treatment can arise from the disease itself and from the therapies used.

• Fecal incontinence. Can result from tumor invasion of the sphincter muscles or from the effects of radiation on sphincter function. Impaired bowel control after chemoradiotherapy significantly affects quality of life in some patients.
• Radiation proctitis. Pelvic radiotherapy can affect the rectal mucosa, causing bleeding, mucous discharge, diarrhea, and pain. It may present in the acute phase of treatment or emerge as a chronic condition years later.
• Sexual dysfunction. Radiation can affect the nerves and blood vessels in the pelvis, causing sexual dysfunction in both men and women. Vaginal stenosis and dryness are among the most common late complications in women.
• Chemotherapy side effects. Nausea, vomiting, fatigue, bone marrow suppression, and increased infection risk are the principal side effects during chemotherapy. Mitomycin C in particular requires careful monitoring for haematological toxicity.
• Permanent colostomy. Patients who require abdominoperineal resection face fundamental changes to daily life with a permanent stoma. Stoma nurses and peer support groups play an invaluable role in helping patients adapt to and manage this change.
• Recurrence. Cancer can return after treatment is completed. Recurrence may be local (in the anal region), regional (in lymph nodes), or distant (in organs such as the liver or lungs). Regular follow-up is critical for detecting recurrence at the earliest possible stage.

Living with Anal Cancer

An anal cancer diagnosis and the treatment process represent a challenging period both physically and emotionally. Multidisciplinary support, careful follow-up, and a strong network of support make this period considerably more manageable.

Managing Treatment Side Effects

Skin reactions, fatigue, diarrhea, and pain are common during chemoradiotherapy. Use the skin care products your treatment team recommends consistently, particularly for the irradiated skin area. Maintaining adequate nutrition can be difficult; a dietitian can provide essential support throughout this period. Diarrhea can be managed effectively; keep your team informed. Aim for adequate rest during treatment, while continuing light activity such as short walks where possible.

Nutrition

Adopt a diet that supports bowel health during and after treatment. If you are experiencing diarrhea during treatment, temporarily reducing fiber and choosing easily digested foods may be helpful. Gradually increase fiber intake during the recovery period. Staying well hydrated supports both treatment tolerability and bowel function.

Psychological Support

An anal cancer diagnosis can provoke anxiety, fear, and depression. Sharing these feelings with a psychologist or psychiatrist rather than suppressing them supports the recovery process. Support groups connecting people with shared experiences are a valuable resource for reducing the sense of isolation. Keeping close family and friends informed about the diagnosis and treatment helps strengthen social support.

HPV Vaccination and Prevention

HPV vaccination is the most powerful primary prevention tool for anal cancer. The vaccine provides strong protection in individuals who have not yet been exposed to the relevant HPV types. It is included in routine vaccination programs in many countries. Vaccination is particularly recommended for HIV-positive individuals and other high-risk groups.

Regular Follow-up

Ongoing oncology follow-up after treatment completion is essential. Physical examination, anoscopy, and where indicated imaging studies are performed more frequently in the first two years (typically every 3 to 6 months) and then annually thereafter. If recurrence symptoms develop (anal pain, bleeding, or a new mass) do not wait for a scheduled appointment; seek evaluation promptly.

Preparing for Your Appointment

Coming prepared to your appointment helps your doctor work more efficiently and ensures the most relevant information is available for diagnostic and treatment planning.

What you can do:

• Note when symptoms began and how they have changed over time
• Mention any previous HPV-related anal lesion, anal fistula, or other anal condition
• Disclose your HIV status and any current antiretroviral therapy
• List all current medications, vitamins, and supplements
• Be honest about your smoking history
• Mention whether you have received an HPV vaccine
• Note any family history of colorectal or anal cancer
• Write down your questions in advance

Questions you may wish to ask your doctor:

• What stage is the cancer and what is the goal of treatment?
• Do you recommend chemoradiotherapy or surgery?
• What side effects should I expect from treatment?
• Will my continence (bowel control) be affected?
• Is there a chance I will need a colostomy?
• How does my HIV status affect the treatment plan?
• How will I be monitored after treatment is completed?
• What is the risk of recurrence?

Questions your doctor may ask:

• How long have you had these symptoms?
• Have you noticed rectal bleeding? What color and how much?
• Have you noticed a lump or swelling near the anus?
• What is your HIV status and are you on antiretroviral therapy?
• Have you previously been found to have an HPV-related anal lesion or dysplasia?
• Do you smoke?
• Have you had cancer treatment or radiation therapy in the pelvic region before?
• Is there a family history of colorectal cancer?